Vaginal candidiasis clinical trials should use seven-day product control -- FDA.
This article was originally published in The Tan Sheet
VAGINAL CANDIDIASIS CLINICAL TRIALS SHOULD USE SEVEN-DAY THERAPY CONTROL, FDA recommends in a draft guidance on evaluating clinical studies of antimicrobials. FDA's Division of Anti-Infective Drug Products recommends that "two statistically adequate and well-controlled multi-center trials establishing equivalence or superiority to an approved product (seven-day regimen that is approved for Rx or OTC)" be conducted, the draft states.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC